Bone marrow was the traditional graft source when we introduced these procedures to South Africa. Technical details were established using rabbits as the experimental model with translation into a formally structured clinical programme at the University of Cape Town, based in the Groote Schuur Hospital, in 1972. Lack of any infrastructure was overcome by the acquisition of the first continuous-flow cell separator in sub-Sahara to provide for granulocyte transfusions. This was shortly followed by creating a dedicated platelet donor panel and establishing a specialized laboratory for clonogenic assays, flow cytometry, and programmed freezing and by including cryopreservation. Development was constant and seamless but four distinct periods are recognizable. First, guided and constantly encouraged by Professor E Donnall Thomas, was the use of an unfractionated mononuclear population derived from multiple sternal and iliac crest aspirations where complications, as in other centres, included rejection and, particularly troublesome, acute as well as chronic GVHD. The second was centred on CsA in association with Professor Jean Borel at Sandoz in Basle, leading to a decrease in the incidence and severity of the latter immunologic phenomena but not to their abrogation. Third was the opportunity of working with Professor Herman Waldmann and Dr Geoff Hale, first in Cambridge and latterly in Oxford, on immunosuppression achieved by ex vivo T-cell depletion within the broad ambit of the Campath users group. It was here that there was pioneered the alternative new approach of adding the anti-CD 52 MoAb only to the graft in what has become known as the in-the-bag technique. The fourth, securely based on early laboratory and clinical experiences, was a switch to the use of PBSCs mobilized into the circulation with stimulatory peptides. In 1995, this original transplant team relocated to a new academic centre in the private sector and has continued to actively refine the programme over the subsequent decade: the facility at Groote Schuur hospital continues independently. Early recognition that accountability for these expensive and high profile procedures was an important obligation led to consecutive transplants being reported to the International and Autologous registries and now continuing to the Centre for Bone Marrow Transplant Research concurrently with the European Bone Marrow Transplant Registry. This disciplined approach has ensured that all data undergo constant audit and, on such a basis, underpin the unbroken accreditation extending over more than three and a half decades. With difficulties in finding sibling donors, a further achievement was the creation of The South African Bone Marrow Registry and now a proposal to also start a national transplant registry that will complement the survey currently being conducted, on a worldwide basis, by the European Group for Blood and Marrow Transplantation. It is concluded that a properly constituted and functioning multidisciplinary team can costeffectively carry out immunohematopoietic stem cell grafting even in an under-resourced country with an outcome approximating that reported from recognized First World reference centres. The caveat is that, outside such comprehensive units, results may be less impressive, thereby arguing for resource allocation being directed to academically designated, rather than incentive-driven, preferred providers. Bone Marrow Transplantation (2008) 42, S125-S132; doi:10.1038/bmt.2008.140 Keywords: immunohematopoietic SCT; introductiondevelopment; South Africa Professor E Donnall Thomas developed the concept and established the technical feasibility of BMT in a canine model. He and his team then courageously pioneered the translation of these orderly research studies into the clinic and first proposed what have become the currently accepted indications. 1, 2 From the start of these activities in Cooperstown to the Public Health Hospital in Seattle and finally to the Fred Hutchinson Cancer, he has through sheer talent inspired leadership and a unique compassion for patients and every member of his staff alike and attracted generations of Fellows, many of whom have gone on to sustain the ever clearer definition for the usage and unravelling of early and now late side effects. The hallmark of these graduates is his clear imprint of identifying a clinical problem and then increasingly applying cellular and molecular biologic techniques to understanding pathogenesis as a basis for refined or focused intervention. Small wonder that such achievements were recognized by the award of the Nobel Prize.
It would be inappropriate to describe the historical parallels that took place in South Africa without the preceding acknowledgement or an explanation of how the programme started in sub-Sahara. During the years as a haematology Fellow in Seattle with Professor Clement A Finch, there was regular contact and exposure to the excitement surrounding BMT. It would be both difficultand invidious-to select from that group of dedicated investigators more than a representative mention of four who remain currently active, including Dr Rainer Storb, Dr Fred Appelbaum, Dr Joachim Deeg and Dr Jean Sanders with whom, among others, we are privileged to maintain an association that now extends back to more than 30 years.
One other event that cannot be overlooked is the momentous achievement of Professor Christian Neethling Barnard in carrying out the first human heart transplant in the world. It was into that receptive environment, prevailing at the University of Cape Town and Groote Schuur Hospital, that one Peter Jacobs had the great honour of being appointed as the Foundation Professor of Hematology. The inevitable question from Sir Richard Luyt and the appointments committee was what direction the new department had selected for particular focus! With no in-depth training in immunology and precious little in transplantation biology, it was with temerity that this emerging area of interest-BM grafting was chosen. And so the die was cast. The brief historical record that follows freely acknowledges unrestricted encouragement from innumerable colleagues of all persuasions, particularly during the early development with periods of frustration balanced by elation, and the many members of the multidisciplinary team who collectively made it a reality. It equally reminds us all never to lose sight of that extraordinary courage shown by patients and their families alike.
From individual centre and case studies to the meticulously orchestrated collection and analysis of data by the Centre for International Bone Marrow Transplant Research, indications in adults and children are now clearly defined (Table 1) , 3 whereas outcome remains the subject of continuous review and updating. 4 Against this background, a number of relevant observations emerge that logically start with patient selection and a consideration of variables including age and comorbidity. It is here that the collective experience of the multidisciplinary team is crucial, with best results reflecting an under-appreciated centre effect. 5, 6 All important is the conditioning of the recipient to accept the incoming graft, but, in selected instances and depending on diagnosis, it may be the need for further chemotherapy directed at eradicating residual disease. Historically, myeloablative preparation with high-dose chemotherapy 7 or irradiation 8 and more innovatively by the use of radioconjugates 9 continues to undergo study. An area of particular interest has been the use of anti-CD 52 MoAb, which can be given either to a patient or a used ex vivo in what has become known as the in-the-bag technique. 10 Recognizing the morbidity and mortality associated with this step has resulted in the description of reduced intensity regimens that make it possible to extend the upper age limit, but this may be offset by higher disease relapse rates. However, a reversal of the latter complication is possible in some cases by capitalizing on antitumour effects mediated by alloreactive T-cells in the form of delayed donor lymphocyte infusion. 11 At this point remains the unresolved and challenging issue of optimum post transplant immunosuppression ranging from traditional corticosteroids with CsA and MTX through a wide range of new and potentially more effective-perhaps even safer-options. 12 This sophisticated form of treatment is best carried out in a dedicated reverse isolation unit or protected environment, but debate rages on precisely what defines such a physical facility or plant. Arguably, of far greater importance is investment in a properly constituted cross-disciplinary management team with, at least in Africa, input from practitioners of alternative or complementary medicine. Also, there is a need for a reliable and safe supply of blood and related products, a laboratory capable and registered as competent to carry out apheresis procedures, experienced in programmed freezing and licensed for cryopreservation in terms of locally promulgated acts for dealing with human tissues. 13 Donor availability, particularly with increasing use of matched unrelated volunteers, and alternative sources including cord blood are those unique considerations securing access to tissue typing with immunogenetics accreditation.
14 Transplants not carried out in such an organized, audited and accredited centre, designated as competent for both harvesting and grafting, are viewed as inappropriate and to be discouraged.
Then, in the short term defined as the first 100 days, is transplant-related mortality, which has a number of Table 1 Traditional indications for transplantations
Aplastic anaemia
Acute leukaemia Myeloid Lymphoid
Myeloproliferative diseases Myelofibrosis
Myelodysplastic syndromes Multiple myeloma
Chronic leukaemia Granulocytic Lymphocytic
Lymphoma Hodgkin Indolent Aggressive
Modified from: Forman SJ. 3 The entry of patients only into clinical trial protocols is strongly favoured. Such structures provide for accountability and outcome analysis upon which rest accreditation. Also inclusive is the all-important quality-of-life evaluation and documentation of time-related side effects.
contributors. 3 These include adequacy of high-resolution histocompatibility matching between the donor and the recipient. Second is the quality of the graft defined in a number of different ways ranging from mononuclear cells to CD 34-expressing population or repopulating potential documented in clonogenic assays as a long-term colonyinitiating cells. Third is the ever-improving supportive care extending from the isolation facility to regular participation of consultants in infectious disease, cardiology and pulmonology coupled with the all-important and dedicated nurses and other paramedical professionals.
Integral to this period, but extending throughout longterm care, is attention to quality of life, which requires specific documentation and typically would involve psychosocial counselling, psychology and liaison psychiatry. As volume and, therefore, referrals increase, there emerges a new aspect in which patients increasingly accept responsibility for their care and work closely with community medical and nursing staff. 15 The sensitivity and considerable thought, as well as an extraordinary amount of communication so vital to achieving success of this exercise, directly impact on continued support and acceptance of the role that the transplant centre plays in an entire region. In the reverse direction is the need for an effective datacapture system vital to make possible correlation of all events with survival. Unless well orchestrated, such limitations assume a disproportionate magnitude in under-resourced countries and place a new and particular onus on those willing to accept responsibility for carrying out these procedures in having to maintain scrupulous follow-up and schedule specialized investigations at clinic visits ( Table 2) .
The cardinal responsibility of transplant teams is to maintain accountability and transparency defined by regular audit on which will be based the accreditation of status as transplant and harvest centres. This requires reporting of consecutive patients to international registries with matching records of activity through national surveys and, additionally, the constant analysis and publication of results. Only in this way can there be any confidence that these hazardous and high cost procedures, increasingly being carried out in the Third World, will approximate standards of care using international norms. Arguments that such criteria do not apply to developing countries, where less good outcome might be condoned, are clearly specious as well as inappropriate! Such an attitude should not be entertained-and much less supported-particularly as there is evidence that precisely the opposite is true. 16, 17 It is against these observations that, first, the introduction and then the continuous development of immunohematopoietic SCT in South Africa over a 35-year period can now be detailed. There emerges the conclusion that at the present time they continue to provide life-saving and cost-effective, as well as resource-appropriate, therapeutic options in selected, properly managed centres that enjoy international designation.
Demographic considerations and current transplant activity
South Africa has a surface area of 1 219 080 km 2 (Table 3 , Figure 1 ) with a population of 47 849 800 and a population density of 135/km 2 . Complete records are available from the time BMT was started by the originally designated team (Table 4) . Now, with the recent proposal that a national database be started, matching activities throughout the Table 2 The annual post transplant evaluation Modified from: Lee S. 15 In the interim, all individuals are seen as frequently as needed, but as a generalization, when asymptomatic, every 3 months. Once a year, more detailed assessment is prudent. country can be collected hopefully through the existing Bone Marrow Registry. 18 Such voluntary participation should, in future, make these activities a matter of general record. At the same time, South Africa has been included in a survey by a questionnaire circulated by the European Bone Marrow Transplant Registry gathering essentially the same figures. Clearly, these two activities need to be complementary. 19 Logically, this exercise is but an initiating step that can easily be extended to formal outcome analysis. Implicit in such a rather more constructive endeavour will be the need to comply with ethics and research rules, including attention to issues that include donor confidentiality. This should be easy given the simple expedient of completing only already available, and circulated, relatively standardized data capture sheets!
Establishment of the Cape Town infrastructure
When this programme was inaugurated in 1970, blood was provided in glass bottles and platelets available only as single unit concentrates. To ensure that adequate transfusion support would be available, an IBM 2990 was secured by donation and this prompt action initiated a long and ongoing collaboration with Professor Jeane Porter Hester. 20 Although initially used for granulocyte transfusion, the apheresis technology rapidly became the anchor, together with the creation of a dedicated volunteer panel for donors, as one of the crucial moves towards realizing clinical transplantation. Physical facilities were limited and the start-up procedures were carried out with literally unlimited encouragement in the newly built block for cardiac transplantation through the courtesy of Professor Christian Neethling Barnard. As a result of his programme, histocompatibility testing also became available having only recently been introduced into our country. It was therefore possible to get class I by serology and some idea of class II by mixed lymphocyte reaction. These shortcomings were appreciated relatively soon and, in close collaboration with Professor Ernette du Toit, high-resolution typing became available with eventual immunogenetic testing approved in her laboratory. 14 The activity of the South African Bone Marrow Registry is reflected in the latest statistics report ( Table 5 ). The technical procedures of marrow processing, including characterization of the recovered mononuclear product, necessitated the development of a rabbit model in association with Professor Bruno Speck and Professor Alois Gratwohl in Basle to refine the methods, and the almost immediate establishment of flow cytometry and clonogenic assays using these transplants between strains showed that acute and chronic GVHD 21 closely paralleled what was being seen in the clinical programme. These manifestations were used to document the effects of CsA just made available by Professor Jean Borel at Sandoz in Switzerland. 22 The same approach proved crucial in evaluating the administration of the Campath series of MoAbs to the recipient but subsequently showing that even more effective immunosuppression was possible by exposing the graft to the protein ex vivo in what has subsequently been described as the in-the-bag technique. 10 This method has emerged as surprisingly rugged in abrogating classical acute GVHD and so substantially diminishing, almost to the point of extinction, the subsequently occurring chronic variant. 23 The clinical programme
The constant development, in a structured and actively evolving series, of experimental and clinical studies fell into four convenient but artificially distinct periods that characterize these activities in sub-Saharan Africa and particularly as chronicled at the University of Cape Town and Groote Schuur Hospital. 16 Unfractionated BM era mirrored experience occurring elsewhere in the world. Engraftment was often successful but plagued by graft failure and substantial morbidity as well as significant mortality consequent upon the syndrome of acute GVHD. Here, an often-profound injury to the skin, biliary endothelium and enterocytes, compounded by severe infection, responded only partially to immunosuppression with corticosteroids and MTX 24 with extension to a severe sclerosing chronic form that created intractable disability in adults and children alike. 23 In addition to the severe disability caused to recipients with devastating disorganization of family life, there emerged a more profound and often underplayed psychological injury to medical and nursing staff alike. This caused high staff turnover and understandable criticism from detractors of transplantation in general and more particularly to the use in hematology with the focus on the perceived worse side effects in children.
Cyclosporin A era started when this undecapeptide was isolated by Jean Borel in Sandoz and with our involvement in some of the earliest investigations of this biological breakthrough that was again thoroughly explored in the rabbit. 25 Here, as also when the experimental studies were translated into the clinic, the incidence and severity, particularly of acute GVHD, was decreased but the broad range of complications changed surprisingly little. Nevertheless, this was a seminal step in being able to reverse the weakening confidence of the local medical community in the role of immunohematopoietic SCT and to set the stage for the continued active exploration of new and more effective agents. 26 Monoclonal antibody or campath era was in many ways the single biggest advance with which we were directly involved. Thus, the opportunity was afforded us of working with Professor Herman Waldmann and Dr Geoff Hale, initially in Cambridge and subsequently in Oxford, through participation in the scientific deliberations of the Campath users group. There was the innovative approach of employing selectively synthesized series of these Igs for the alternative approach of effecting immunosuppression by means of relatively selective T-cell depletion. Experience in the animal transplant model, initially with the lytic IgM protein, shewed GVHD to be beneficially affected and this could be duplicated in human allograft recipients with improvement in outcome. These events were enhanced first by the use of the opsonic IgG and then, more recently, by the humanized chimeric protein, confirmed in other countries. Figure 2 Overall survival in children. Kaplan-Meier analysis shows that at 6.8 years there is a stable plateau consistent with cure. It is notable that results are similar for idiopathic aplasia, Fanconi anemia and AML with nonsignificant differences for lymphoblastic leukemia and the remaining cases. There is also no difference in outcome for graft source but a slight benefit for the female gender, which did not attain statistical significance.
Bone marrow exposed to Campath 1-G-in-the bag Peripheral blood exposed to Campath 1-H-in-the-bag Percentage surviving Figure 3 Overall survival in adults. One of the more interesting aspects of this programme is the similarity in survival by Kaplan-Meier analysis between consecutive patients with BM exposed to Campath 1-G-in-thebag, peripheral blood treated with the same Ig or humanized variant and autografts. This particular approach is notable for the lower level of GVHD, and high remission rates in AML, but with an increasing incidence of CMV positivity that is the subject of ongoing investigation.
At about the midpoint of these collaborative studies, innovative experimental evidence in our laboratory demonstrated that the addition of Ig to the graft, before infusion alone and without any subsequent immunosuppression using antibody or drugs, impacted favourably on acute GVHD. This syndrome virtually disappeared, although a late-presenting mild acute variant was recognized limited to the skin, being grade 1 and typically responding to topical steroids but seldom needing systemic administration. This was the birth of the in vitro, ex vivo or, as it has subsequently become known, Campath in-the-bag technique. 10 Overlapping with these developments was the recognition that a stem cell population having many characteristics similar to those derived from the BM could be obtained by the much simpler expedient of recovery from the peripheral circulation using apheresis technology, with enhancement resulting from the donor receiving stimulatory peptides in the form of G-CSF. 28 A new observation emerged in that CMV infections, which had not been particularly prominent while using marrow, now required increased constant monitoring and prompt administration of gancyclovir to avoid progression from viraemia to the much more hazardous situation of clinical disease typically in the lung or the gastrointestinal tract.
The current era, spanning the last 12 years, has been particularly illuminating in the context of an underresourced area where state support for teaching hospitals continues to relentlessly erode so that commercial ventures have become more receptive to accepting tertiary-level 30 The experiment has been successful, proving that it is realistic to maintain the consecutive patient reporting system first to the International and then to the Autologous registries that are currently combined into the Centre for Bone Marrow Transplant Research. This period demonstrates the feasibility of meeting the audit criteria for continued accreditation as both a transplant and harvest centre now extending for an unbroken period in excess of three decades, as well as accommodating the need for matched unrelated volunteer donors. The latter sparked the need to start a donor registry that has become a national entity providing tissue-typing services for other centres in the country, regularly interacting with corresponding facilities and participating in searches from elsewhere in the world with activity recently updated. 31 The standard is such that endorsement is maintained from the American National Donor Programme as well as the European Bone Marrow Transplant Registry. In parallel outcome has been analysed and reported in both children 32 ( Figure 2 ) and adults 33 ( Figure 3 ). whereas the particular relevance of these procedures in patients with lymphoma continues to attract our ongoing and special attention. 34, 35 An important consideration in the Third World is to balance the need for these high cost procedures against resources available in state hospitals having a limited budget and a competing private sector where restraints are of a slightly different nature dictated by the particular insurance plan available through managed health care. In order that some idea of national activity can be gauged, it was recently proposed that a BM transplant registry be established within the ambit of the existing national body, the South African Bone Marrow Registry. The argument in favour of such a base is that it would allow comprehensive or inclusive recording of autologous and all forms of allogeneic transplantation and include alternative sources, such as cord blood and matched unrelated volunteer donors, and do so in a non-partisan way. It would also permit the government, through the Department of Health, access to reliable statistics as to activity of the teams, whether they be in university hospitals or private sectors. Additionally, it would anticipate future needs for appropriate regulation that may be promulgated in terms of the Human Tissues Act. Here, particular issues relate to harvesting, any form of processing or manipulation of grafts and subsequent cryopreservation while monitoring the movement of these human products not only within the country but also as a cross-border between countries through the medium of collaborating international registries.
Conclusion
The basis for this national experience can be factually recorded in three phases of past achievement and present status with a projection for the future. Historically, the experimental hematology and subsequent systematic translation into the clinical programme documents the capability of an under-resourced country to provide advanced and life-saving interventions as dictated only by the genuine needs within the community, across the age spectrum and catered for by the state or private sector, even where costs are a major consideration (Tables 5 and 6) . It is equally clearly demonstrated that in those few facilities that have elected to meet the criteria for ongoing audit and accreditation from international peers, designation is possible as a donor and harvest centre leading to participation in a worldwide community linked through registries that share search and provision of matched unrelated volunteers when these are not available locally. Finally, it is time to survey the activity within our borders and to this end the reporting of consecutive procedures by each practice has proposed forming a registry to operate within the ambit of the nationally constituted South African Bone Marrow Registry. The latter initiative is given sharp focus by a similar approach already launched by the European Bone Marrow Transplant Registry, and both should be mutually complementary. Such a proactive move would have the capacity for expansion to document outcome, although this would require appropriate ethics and research monitoring. A further attraction is the creation of a reliable database providing comparisons between different regions of the world and, in the local context, a basis to guide and educate practices in terms of regulation for transfusion practices and handling human tissues. The natural end point becomes academic recognition for properly accredited programmes to safeguard future scientific and training requirements while simultaneously reducing any need for commercial or incentive-driven providers.
